Home' Forge : Vol 1 No 1 Contents business.gov.au
Delivered by AusIndustryTM
GENEROUS, EASY TO ACCESS SUPPORT
ABR (Australian BioRefining) Process Development is an
internationally recognised chemical process and technology
development company based in Evans Head, New South Wales.
Specialising in developing innovative and economic solutions for removing waste
chemicals from industrial processes, ABR Process Development is adding value to the
mining, manufacturing and energy industries in Australia and overseas.
With proposals for projects in Serbia and South Africa, and patents covering the
application of its technology worldwide, ABR Process Development is currently in
discussions with some of the world’s biggest players in the chemical industry.
The company, which has up to 12 employees working on its various research and
development projects, grew from humble beginnings as a one-person operation in a
small tin shed in 2004.
“At first our business plan didn’t foresee any revenue for four years,” says CEO Adam
Blunn. “In the last couple of years we’ve experienced a turnover of about one million
dollars per year.”
Research and development is core to ABR Process Development’s business, and the
company has accessed support from the Australian Government’s R&D Tax Incentive
“As a small company, the R&D Tax Incentive has given us a greater ability to undertake
projects we wouldn’t have been able to do otherwise,” said Mr Blunn. “Thanks to the
program we’ve gained some extra cash flow on an annual basis, which has helped us
manage some of the risk involved.”
on human trials
Early stage Australian drug development company Paranta
Biosciences Limited (Paranta) is developing a potentially
life-saving biotherapeutic derived from a naturally occurring
glycoprotein found in many cells in the body.
Paranta is initially targeting the treatment of lung diseases associated with
inflammation and fibrosis (tissue scarring).
The development of Paranta’s therapeutic technology was supported by the R&D Tax
Incentive, and Paranta CEO, Ross Barrow, says this assistance has helped the business
“The development of a new biological drug is incredibly expensive, and the availability
of capital to fund early stage ventures in this country is limited and difficult to secure,”
Mr Barrow said. “Without assistance from the R&D Tax Incentive, Paranta may have
been forced to prematurely sell off our intellectual property assets or otherwise
relocate the company offshore.”
“The R&D Tax Incentive has been critical to the progress we have made to date, and
has helped Paranta get to the point where we can begin clinical trials in humans.”
Trials will focus on diseases such as cystic fibrosis, chronic bronchitis, emphysema,
idiopathic pulmonary fibrosis, pulmonary hypertension as well as severe forms of
asthma. Paranta’s biotherapeutic also has the potential to treat a much wider range
of deadly and debilitating conditions associated with inflammation; from sepsis
(septicaemia), inflammatory bowel diseases such as ulcerative colitis and Crohn’s
disease, cirrhosis of the liver, tissue damage sustained during organ transplantation, to
the reversal of muscle wastage (cachexia) which accompanies chronic illnesses such as
cancer amongst many others.
“The potential of Paranta’s therapeutic technology is extraordinarily large,” Mr Barrow
said. “The size of the global inflammatory therapeutics market was around US$58
billion in 2010 and is projected to increase to above US$85 billion in 2017. Our main
focus is the treatment of respiratory diseases which affect an estimated 300 million
“According to a report by the World Health Organisation, lower respiratory infections
and chronic pulmonary obstructive diseases such as chronic bronchitis and emphysema
caused almost 7 million deaths in 2008; second only to ischemic heart disease.
“The 2010 market for pulmonary therapeutics was US$29 billion and is projected
to increase to over US$36 billion in 2017. Approximately half of this market is
poorly served by current therapies and it is in these indications that we believe our
biotherapeutic will achieve significant health benefits for patients.”
In mid-2014 Paranta raised AUD$3 million from shareholders which will provide the
company with sufficient funds to undertake its first clinical trial.
The R&D Tax Incentive
The R&D Tax Incentive is a generous,
easy-to-access entitlement available
to eligible businesses of all sizes in all
The programme offers:
• a 45 per cent* refundable tax
offset for eligible small to medium
companies with an annual turnover
of less than $20 million per annum
• a 40 per cent* non-refundable
tax offset to other eligible businesses.
* On 12 February 2015, Parliament approved a $100 million threshold on R&D expenditure claims,
effective from 1 July 2014. For expenditure above $100 million, companies will be able to claim
a tax offset at the prevailing company tax rate. The Australian Government has also announced
its intention to change the rates of assistance to 43.5 and 38.5 per cent respectively. This change
requires further legislation.
“The R&D Tax
been critical to
the progress we
have made to
327992A_Dept Industry | 2156.indd 2
25/02/15 8:50 AM
Links Archive Vol 1 No 2 Navigation Previous Page Next Page